REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
8

GHK-Cu Results — Honest Assessment

Logan Barnes·about 2 months ago
Giving my honest GHK-Cu results because I think this community needs more realistic reports alongside the glowing reviews. Background: 42-year-old, moderately active, primary goals were recovery and general health optimization. Positives: Sleep improved meaningfully. This was the most consistent and obvious benefit. I also noticed better recovery from workouts, though this is harder to quantify objectively. Joint comfort improved — morning stiffness that I attributed to age decreased noticeably. Neutrals: mood and energy had minor improvements that could also be attributed to better sleep. Hard to isolate causation. Negatives: cost is significant. Injection site irritation was annoying for the first few weeks. The daily routine of reconstitution, dosing, and tracking takes more time and mental energy than I expected. Overall verdict: GHK-Cu delivered on its primary claims for me, but the magnitude of effects was moderate, not transformative. If your expectations are calibrated for a 15-20 percent improvement in target areas rather than a complete overhaul, you will probably be satisfied.

Comments (3)

Ember CarrollDEMO·about 2 months ago

Thanks for sharing the science behind GHK-Cu. I think the mechanism explanation really helps people understand why patience is necessary with these protocols. It is not like taking a painkiller where you feel effects in 30 minutes — you are initiating biological programs that take weeks to fully manifest.

3
Dylan FloydDEMO·about 2 months ago

I have been stacking GHK-Cu with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

4
Flint CassidyDEMO·about 2 months ago

Real talk: GHK-Cu worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

5

Sign in to comment.